Clinical study of healthy human CIK in the treatment of advanced non-small cell lung cancer

Qi Yanchao

Cell Therapy Laboratory, International Metabolic Disease Research Center, Southern Medical University

Abstract:Objective: Lung cancer accounts for the first place in cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers, and more than 70% of patients are diagnosed at an advanced stage. At present, autologous CIK combined with chemotherapy in the treatment of NSCLC has been widely used in clinical. However, the clinical efficacy is not satisfactory; the total effective rate is about 30%, the median overall survival time is only 8.5 months, and the clinical cure rate is almost zero. Therefore, it is particularly important to study the difference between the expansion speed, cell phenotype and killing activity of CIK cells from healthy people and CIK cells from tumor patients, and to explore new tumor immunotherapy methods. The purpose of this paper is to investigate the therapeutic effect of healthy human CIK cells on advanced NSCLC. Methods: Twelve healthy donors were selected. Peripheral blood mononuclear cells were collected to prepare healthy human CIK cells for the treatment of 12 patients with advanced NSCLC. At the same time, autologous peripheral blood mononuclear cells were collected to prepare CIK, and the amplification speed, cell phenotype and killing activity of CIK cells were compared between the two. Results: The expansion rate of healthy human CIK cells reached 125 times in 14 days, which was significantly higher than that of NSCLC patients by 69 times. The proportion of CD3CD56 double positive cells in healthy human CIK cells was 35%, which was significantly higher than that in NSCLC patients. The killing activity of healthy CIK cells to K562 was 86%, which was significantly higher than that of NSCLC patients...More

Key words:CIK;healthy people;Cell phenotype;Killing activity;NSCLC;Advanced non-small cell lung cancer;

Conference Name:Research and Practice: The 8th World Cancer Congress 2015

Meeting time:2015-05-15

Venue:Beijing, China

Album:Medical and Health Science and Technology

Topic:Oncology

Classification number:R734.2

Clinical Preliminary Study of Healthy Human CIK in the Treatment of Advanced Non-small Cell Lung Cancer_Qi Yanchao. pdf